ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,921.30
0.76%
S&P ASX All Technology
3,078.20
0.32%
Brent Oil
79.745
0.00%
US Dollar vs AUD
1.52742
0.00%
Bitcoin
67,893.17
-0.03%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateTimeSourceHeadlineSymbolCompany
25/07/202421:00Business WireAstraZeneca’s H1 and Q2 2024 Financial ResultsNASDAQ:AZNAstraZeneca PLC
25/07/202420:21IH Market NewsU.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire ExpectationsNASDAQ:AZNAstraZeneca PLC
25/07/202420:19IH Market NewsEarnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5%NASDAQ:AZNAstraZeneca PLC
23/07/202421:00PR Newswire (Canada)Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysisNASDAQ:AZNAstraZeneca PLC
23/07/202421:00PR Newswire (Canada)Voydeya est approuvé au Canada à titre de traitement d'appoint au ravulizumab ou à l'éculizumab chez les adultes atteints d'une maladie rare, appelée HPN, qui présentent une anémie hémolytique résiduelle attribuable à une hémolyse extravasculairNASDAQ:AZNAstraZeneca PLC
25/06/202421:00Business WireIMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trialNASDAQ:AZNAstraZeneca PLC
17/06/202421:00Business WireIMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancerNASDAQ:AZNAstraZeneca PLC
16/06/202421:00Business WireCALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trialNASDAQ:AZNAstraZeneca PLC
13/06/202407:35Business WireFARXIGA approved in the US for the treatment of pediatric type-2 diabetesNASDAQ:AZNAstraZeneca PLC
13/06/202400:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
10/06/202421:00Business WireTAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancerNASDAQ:AZNAstraZeneca PLC
06/06/202421:00PR Newswire (US)I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical OfficerNASDAQ:AZNAstraZeneca PLC
05/06/202406:23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
05/06/202400:02Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:AZNAstraZeneca PLC
04/06/202423:10IH Market NewsEconomic Worries May Lead To Weakness On Wall StreetNASDAQ:AZNAstraZeneca PLC
04/06/202421:00PR Newswire (US)AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024NASDAQ:AZNAstraZeneca PLC
04/06/202400:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
04/06/202400:23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
03/06/202420:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
03/06/202404:32Business WireTAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trialNASDAQ:AZNAstraZeneca PLC
02/06/202422:05Business WireIMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placeboNASDAQ:AZNAstraZeneca PLC
02/06/202422:00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapyNASDAQ:AZNAstraZeneca PLC
29/05/202406:30GlobeNewswire Inc.Cellectis Reports Financial Results for First Quarter 2024NASDAQ:AZNAstraZeneca PLC
28/05/202423:06Business Wireダトポタマブ デルクステカン、 進行性非扁平上皮非小細胞肺癌患者に対する第III相TROPION-Lung01試験において、 化学療法と比較して臨床的に有意な全生存期間の改善を示すNASDAQ:AZNAstraZeneca PLC
28/05/202420:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
28/05/202406:55Business WireDatopotamab-Deruxtecan zeigt in Phase-III-Studie TROPION-Lung01 klinisch signifikante Verbesserung des Gesamtüberlebens im Vergleich zur Chemotherapie bei Patienten mit fortgeschrittenem nicht squamösem, nicht kleinzelligem LungenkrebsNASDAQ:AZNAstraZeneca PLC
28/05/202403:14Business WireLe datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameuxNASDAQ:AZNAstraZeneca PLC
27/05/202421:00Business WireDatopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trialNASDAQ:AZNAstraZeneca PLC
24/05/202403:52Business WireAstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)NASDAQ:AZNAstraZeneca PLC
23/05/202421:00Business WireAstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)NASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Your Recent History

NYSE
NKE
Nike
ASX
RIO
Rio Tinto
NYSE
MCD
McDonalds
ASX
XMM
S&P ASX 300 Metals and M...
SPI
SP500
S&P 500
FTSE
UKX
FTSE 100
FX
AUDUSD
AUD vs US Dollar
ASX
FMG
Fortescue
NYSE
KO
Coca Cola
ASX
XFL
S&P ASX 50
ASX
SUN
Suncorp
ASX
NAB
National Australia Bank
ASX
WES
Wesfarmers
ASX
AMP
AMP
ASX
ORG
Origin Energy
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved